Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

ClinicalTrials.gov ID: NCT00532441

Public ClinicalTrials.gov record NCT00532441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101

Study identification

NCT ID
NCT00532441
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gabi Chiorean, MD
Other
Enrollment
25 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Erlotinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update posted
Feb 11, 2016

2007 – 2010

United States locations

U.S. sites
12
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
Helen F. Graham Cancer Center Newark Delaware 19713
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
Rush-Presbyterian St. Luke's Medical Center Chicago Illinois 60612
Cancer Care Center of Southern Indiana Bloomington Indiana 47403
Fort Wayne Oncology & Hematology, Inc Fort Wayne Indiana 46815
IN Onc/Hem Associates Indianapolis Indiana 46202
Indiana University Cancer Center Indianapolis Indiana 46202
Quality Cancer Center (MCGOP) Indianapolis Indiana 46202
Medical Consultants, P.C. Muncie Indiana 47303
Northern Indiana Cancer Research Consortium South Bend Indiana 46601
Siteman Cancer Center St Louis Missouri 63110
Methodist Cancer Center Omaha Nebraska 68114

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00532441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2016 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00532441 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →